Analyst ratings, especially from major financial institutions like Barclays, can significantly influence investor sentiment and stock prices. An Overweight rating suggests that Barclays believes Cardinal Health's stock will outperform the average return of the stocks in the analyst's coverage universe. The announcement of a price target of $117, which is presumably higher than the current trading price, indicates an expectation of upward movement in the stock's price, which could lead to increased investor interest and a potential short-term price increase.